KMDA· Health Care› Drug Manufacturers - Specialty & Generic

Kamada Ltd.

Stage 2 · Advancing · week 5

As of Oct 22, 2026, Kamada is in Stage 2, the uptrend phase, now in week 5 (since Sep 24, 2026). It closed at $7.73, 12.9% below its 52-week high and below its 200-day average, which is rising.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. More about the company

$7.73

-0.51% today

$446M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Early entry: still early enough in its move

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 26 in Drug Manufacturers - Specialty & Generic · #1 of 272 in Health Care

Is KMDA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 19w

S2 18w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 9w → S3 4w → S4 5w → S1 1w → S2 13w → S3 9w → S4 6w → S1 7w → S2 2w → S1 1w → S4 6w → S1 2w → S2 19w → S3 10w → S2 12w → S3 5w → S4 9w → S1 3w → S2 18w → S3 9w → S4 6w → S1 4w → S2 4w current

Total tracked: 164 weeks across 23 stage runs.

KMDA among Drug Manufacturers - Specialty & Generic21st of 84 by relative strength

All 84 →

Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	CPIXCumberland Pharmaceuticals Inc.	Stage 2 · wk 23	98	+6.8%
2	ETONEton Pharmaceuticals, Inc.	Stage 2 · wk 30	97	−10.1%
3	ANIKAnika Therapeutics Inc.	Stage 2 · wk 15	96	+3.5%
4	IRWDIronwood Pharmaceuticals, Inc. Class A	Stage 3 · wk 3	96	−16.4%
5	TEVATeva Pharmaceutical Industries Limited	Stage 2 · wk 9	95	+3.1%
6	AMRXAmneal Pharmaceuticals, Inc. Class A	Stage 2 · wk 19	95	+5.9%
7	KNSAKiniksa Pharmaceuticals International, plc Class A	Stage 2 · wk 73	95	+6.2%
8	AMLXAmylyx Pharmaceuticals, Inc.	Stage 2 · wk 15	93	−6.6%
…21	KMDAKamada Ltd.	Stage 2 · wk 5	68	−11.9%

vs 52W High

-12.9%

$6.29 lo$8.87 hi

12.9% below 52W high, pullback range

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 5

1w13w26w

Week 5, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

-1.3%

200 DMA: $7.83 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.34x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-11.9%

+11.8%

-4.6%

YTD

+15.6%

+17.3%

Scan Membership

Breakout Watch

Latest: 2025-06-17

11 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 5 · Vol 0.34x

2026-10-21S2

Wk 4 · Vol 0.34x

2026-10-20S2

Wk 4 · Vol 0.77x

2026-10-19S2

Wk 4 · Vol 0.35x

2026-10-16S2

Wk 4 · Vol 0.29x

2026-10-15S2

Wk 4 · Vol 0.43x

2026-10-14S2

Wk 3 · Vol 0.42x

2026-10-13S2

Wk 3 · Vol 0.61x

2026-10-12S2

Wk 3 · Vol 0.30x

2026-10-09S2

Wk 3 · Vol 0.51x

2026-10-08S2

Wk 3 · Vol 0.48x

2026-10-07S2

Wk 2 · Vol 0.52x

Moving averages & range

50 DMA

$8.14

200 DMA

$7.83

52W High

$8.87

52W Low

$6.29

5D Low

$7.61

Resistance levels (recent highs)

20d High

$8.72

60d High

$8.87

120d High

$8.87

250d High

$8.87

Next resistance

+12.8%

to 20d High

P/E (TTM)

20.3

Forward 13.4

Earnings Growth (YoY)

+23.1%

Revenue +22.7%

ROE

+8.4%

Profit margin +11.6%

Dividend Yield

2.18%

P/B 1.7

Kamada: quick answers

What stage is Kamada in?

As of Oct 22, 2026, Kamada (KMDA) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 24, 2026 and is in week 5. What the four stages mean

Is Kamada in an uptrend?

Yes. Kamada is in a Stage 2 uptrend. It trades 1.3% below its 200-day average, which is rising.

How far is Kamada from its 52-week high?

Kamada closed at $7.73 on Oct 22, 2026, 12.9% below its 52-week high of $8.87. Its 52-week low is $6.29.

How has Kamada performed over the past year?

As of Oct 22, 2026, Kamada is up 17.3% over the past year and up 15.6% so far in 2026.

Which sector and industry is Kamada in?

Kamada is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.